&w=3840&q=100)
ITC Hotels Q1 FY26 result: Net profit jumps 54% to ₹133 cr, revenue up 15%
New Delhi
ITC Hotels on Wednesday reported a consolidated net profit of ₹133.10 crore for the quarter ended June 2025 (Q1 FY26), marking a 53.8 per cent increase year-on-year (Y-o-Y) from ₹86.53 crore. However, profit declined sequentially 48.2 per cent compared to ₹256.90 crore in the March 2025 quarter (Q4 FY25), according to a BSE filing.
The company's revenue increased 15.5 per cent Y-o-Y to ₹815.54 crore in Q1 FY26, up from ₹705.84 crore in Q1 FY25. On a sequential basis, revenue fell 23.1 per cent from ₹1,060.62 crore posted in the previous quarter.
Shares of ITC Hotels were trading 6 per cent higher at ₹241.95 apiece on the BSE at 2.40 pm on Wednesday.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
Ceat Q1 FY26 results: Profit falls 27% to ₹112 crore, revenue up 10.5%
Ceat on Thursday reported a consolidated net profit of ₹112.45 crore for Q1 FY26, down 27 per cent year-on-year (y-o-y) from ₹154.16 crore in Q1 FY25. However, the tyre maker's profit improved sequentially from ₹99.49 crore in Q4 FY25, according to a BSE filing by the company. The company's revenue for the quarter increased to ₹3,529.41 crore, up 10.5 per cent y-o-y from ₹3,192.82 crore and 3.2 per cent sequentially from ₹3,420.62 crore. On the expenditure end, the company spent ₹3,375.10 crore in the quarter, up 12.4 per cent from ₹3,003.56 crore in the same quarter last year. Sequentially, the expenses increased 3.6 per cent from ₹3,259.26 crore. Commenting on the quarter performance, Arnab Banerjee, managing director and chief executive officer at Ceat, said, 'We continue to grow at a strong pace with double-digit growth in top-line, driven by OEM and replacement segments. Looking ahead, we are well poised to ride the premiumisation and electrification trend in the domestic market, and renew our growth in international markets with stability in the geopolitical situation.' The company also announced the re-appointment of Banerjee for a further term of two years, starting April 1, 2026. Adding to it, Chief Financial Officer Kumar Subbiah said that the revenue growth came on the back of an increase in demand from original equipment manufacturers (OEM) and replacement segments. "As Q1 is a marketing-heavy quarter with significant marketing costs associated with IPL, operational margins saw a slight dip. Efficient cash flow management helped in gross debt coming down by ₹100 crore during the quarter," Subbiah said. Ceat plans ₹450 crore capex for plant expansion Separately, the company proposed a capital expenditure of ₹450 crore to expand capacity at its Chennai plant by around 35 per cent in the passenger car and utility vehicle (PCUV) segment. The expansion, expected to be completed by the end of FY 2027, will be funded through a mix of internal accruals and debt, according to the BSE filing.
News18
an hour ago
- News18
Anthem Biosciences IPO Subscribed 77% On Day 1: Apply Or Not? Check Price, GMP, Review
Last Updated: The GMP of the Anthem Biosciences IPO currently stands at 17.54%, indicating strong listing gains. Should I Subscribe To Anthem Biosciences IPO? The initial public offering of Anthem Biosciences Ltd opened today, Monday, July 14. The price band of the mainboard IPO, which aims to raise Rs 3,395 crore, has been fixed in the range of Rs 540 to Rs 570. On the first day of bidding on Monday, the issue received a 0.77 times subscription, garnering bids for 3,22,28,066 shares as against the 4,17,50,321 shares on offer. The retail and NII participation stood at 0.62x and 1.64x, respectively. The QIB category received a 0.39x subscription. The IPO's grey market premium currently stands at 17.54%, indicating strong listing gains. The three-day IPO will be closed on July 16. Anthem Biosciences Ltd, a CRDMO founded in 2006, offers end-to-end drug discovery-to-manufacturing services and specialises in fermentation-based active pharmaceutical ingredients (APIs) for global pharma and biotech clients. Anthem Biosciences IPO GMP Today According to market observers, unlisted shares of Anthem Biosciences Ltd are currently trading at Rs 670 against its upper IPO price of Rs 570. It means a grey market premium or GMP of Rs 100, which is 17.54% over its issue price, indicating strong listing. The GMP is based on market sentiments and keeps changing. 'Grey market premium' indicates investors' readiness to pay more than the issue price. The price band of the IPO has been fixed in the range of Rs 540 to Rs 570 apiece. Its minimum lot size is 26. It means investors will have to apply for a minimum of 26 shares or in multiple thereof. Retail investors require a minimum capital of Rs 14,040 to apply for the IPO. Anthem Biosciences IPO Allotment And Listing Dates The basis of allotment of the Anthem Biosciences IPO will be finalised on July 17. Its shares will be listed on both BSE and NSE, July 21. Anthem Biosciences IPO: Should You Apply? Brokerages remain largely optimistic about Anthem Biosciences' initial public offering, citing its strong financial track record, niche positioning in the CRDMO space, and robust pipeline. However, a few have flagged concerns over valuations and margin pressures. Aditya Birla Money has recommended a 'subscribe' rating, emphasising the company's leadership team, molecule pipeline, and strategic capacity expansion. 'Anthem's customer profile and molecule pipeline provide long-term demand visibility reinforced by strategic capacity expansion." However, it cautioned that growth is dependent on the success of pipeline molecules and regulatory compliance, among other risks. Anand Rathi Shares & Stock Broking noted that Anthem is 'positioned to cater in CROs and CRDMO segment — the crucial players in the pharma and biotechnology industries — wherein it is being niche player with high entry barriers through its differentiated FFS model, long-term relationship, strong R&D, innovation and technology-driven approach." The brokerage firm added that the company has outperformed peers in profitability and is likely to maintain that edge, assigning a 'subscribe' rating. SBI Securities echoed the sentiment, highlighting that the IPO is valued at a P/E of 70.9x FY25 earnings and appears fairly priced compared to peers. It said, 'It is well placed to encash on the fast-growing CRDMO industry on the back of capacity expansion plans and funding in place; well established track record of profitable growth; and strong business pipeline." Canara Bank Securities offered a 'subscribe for long term' recommendation, citing a strong CAGR of 32% in revenue and 8% in PAT between FY23 and FY25. It emphasised Anthem's FFS model and ESG initiatives, saying, 'The issue is fairly priced, which is at a discount of its listed peers." SMIFS pointed to the doubling of capacity and deeper penetration into regulated markets as key growth drivers. 'The doubling of capacities in the first phase of capex and then another round of capex will propel the company into the league of the largest fermentation players in India," it noted while recommending a long-term subscribe. Ventura Securities was bullish on the sectoral opportunity, stating that 'Anthem Biosciences is exceptionally positioned to capitalize on the fast-growing global CRDMO market, projected to expand at a CAGR of 9.1% from $213.1 billion in 2024 to $330 billion by 2029." It also highlighted Anthem's 95.59% FFS contract success rate and regulatory certifications from USFDA, ANVISA, and ISO. Swastika Investmart pointed out the company's high valuation but justified it due to Anthem's fermentation capacity and global clientele. 'Well-positioned in a high-growth sector with robust financials and global client relationships… subscribe for the listing gains and long term," it advised. Recommending investors to 'Subscribe' for long term, Mehta Equities research analyst Rajan Shinde said, 'We believe the Anthem Biosciences IPO brings investors an opportunity to invest in the high-growth CRDMO space, uniquely positioned with fully integrated capabilities across small and large molecules, including NCE and NBE platforms — a rarity in India. We think with a strong track record of over 8,000 projects, deep engagement with more than 675 clients, and a robust pipeline of 242 active projects, Anthem has demonstrated sustained innovation through early adoption of advanced modalities like ADC, RNAi, and flow chemistry, and a leadership position in green chemistry." The IPO is entirely an offer-for-sale (OFS). So, the company will not receive any funds from the issue and the proceeds will go to the selling shareholders. Anthem Biosciences raised Rs 1,016 crore from anchor investors ahead of its initial share-sale opening for public subscription. Some of the investors that participated in the anchor book are — Abu Dhabi Investment Authority, Government Pension Fund Global, Eastspring Investments, Amundi Funds, PineBridge Global Funds and Societe Generale, HDFC MF (MF), ICICI Prudential MF, Axis MF, UTI MF, Quant MF and Motilal Oswal MF. Anthem is into innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. It also manufactures and sells complex specialized fermentation-based Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars. Sai Life Sciences Ltd, Syngene International, Suven Life Sciences and Divi's Laboratories are the listed peers of Anthem Biosciences. JM Financial, Citigroup Global Markets India, J P Morgan India and Nomura Financial Advisory and Securities (India) are the book-running lead managers for the issue. Stay updated with all the latest business news, including market trends, stock updates, tax, IPO, banking finance, real estate, savings and investments. Get in-depth analysis, expert opinions, and real-time updates—only on News18. Also Download the News18 App to stay updated! tags : initial public offering (IPO) IPO view comments Location : New Delhi, India, India First Published: July 14, 2025, 11:35 IST News business » ipo Anthem Biosciences IPO Subscribed 77% On Day 1: Apply Or Not? Check Price, GMP, Review Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
News18
an hour ago
- News18
Waaree Renewable Tech Q1 FY26 Results: Profit Up 207%; Revenue Doubles to Rs 603 Cr
Last Updated: Waaree Renewable Technologies Ltd reported a net profit jump to Rs 86.38 crore in Q1 FY26, up from Rs 28.16 crore last year. Waaree Renewable Tech Q1 FY26 Results: Waaree Renewable Technologies Ltd (WRTL) on Thursday reported that its net profit jumped 207 crore to Rs 86.38 crore in the first quarter of FY2025-26, compared to Rs 28.16 crore in the same period last year. Consolidated revenue from operations surged 155% YoY to Rs 603 crore, up from Rs 236 crore in Q1FY25, driven by strong EPC project execution and higher power sales. Following the Q1 FY26, shares of Waaree Renewable Technologies Ltd fell 1.62 per cent on BSE to trade at Rs 1184.05 apiece. The scrip earlier opened at Rs 1233.85 apiece compared to the previous day close at Rs 1203.50 apiece. Shares gained 18 per cent in the past five sessions. Waaree Renewable Technologies Ltd has a market cap of Rs 12343 crore. Its IPO came last year. EBITDA (calculated as PBT + finance cost + depreciation – other income) stood at approximately Rs 113.97 crore, registering a jump of over 191% YoY from Rs 39.17 crore in the same period last year. Improved project scale and operating efficiency helped boost margins. Despite a one-time exceptional charge of Rs 4.02 crore related to GST interest, the company posted a profit before tax (PBT) of Rs 116.57 crore, up from Rs 39.27 crore in Q1FY25. Segment-wise, revenue from EPC contracts rose from Rs 228.66 crore to Rs 594.40 crore—a growth of nearly 160%. Power sales also increased by over 14%, from Rs 7.70 crore to Rs 8.79 crore. On the strategic front, WRTL announced an investment of Rs 7.98 crore for a 3.23% stake in Smart Joules Pvt Ltd, marking its expansion into energy efficiency alongside renewables. The Company offers energy savings by providing cooling solutions to building and factories. Investment is part of WRTL' s strategic initiative to expand its presence and strengthen its capabilities across the renewable energy and energy efficiency ecosystem. SJPL operates in a complementary sector aligned with WRTL' s long-term vision of integrated clean energy solutions. view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
